vTv Therapeutics Q3 net loss widens to $11.6 million; no quarterly revenue
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per share, up from $8.7 million, or $1.08 per share, a year earlier, with no revenue in either quarter. Research and development and general and administrative expenses both rose, and cash fell to $77.2 million from $88.9 million at December 31, 2025, which the company says is sufficient to fund operations well through the Phase 3 CATT1 topline readout expected in mid 2027.
Key points
- Q3 2026 net loss attributable to vTv shareholders was $11.6 million ($0.94 per share), compared with $8.7 million ($1.08 per share) in Q3 2025.
- R&D expenses rose to $7.5 million from $7.0 million; G&A expenses rose to $4.9 million from $3.7 million.
- Cash and cash equivalents were $77.2 million at September 30, 2026, versus $88.9 million at December 31, 2025.
- Nine-month 2026 revenue was $36.8 million, compared with none in the prior-year period, per the statement of operations.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.